Anti-related-to-receptor tyrosine kinase (ryk) antibodies and uses thereof
AssigneeThe Regents of the University of California
InventorsThomas J. KIPPS, George F. WIDHOPF, II
Life of this patent
Estimating the term…
Abstract
Provided herein are, inter alia, antibodies, which bind Related-to-Receptor Tyrosine Kinase (Ryk) with high efficiency and specificity. The antibodies and antibody compositions provided herein include, for example, novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other RYK-related diseases. In embodiments, the anti-RYK antibodies provided herein are capable of binding a human RYK protein, but not a mouse RYK protein.
Claims52
An anti-RYK antibody comprising a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain comprises a CDR H1 as set forth in SEQ ID NO:1, a CDR H2 as set forth in SEQ ID NO:2, and a CDR H3 as set forth in SEQ ID NO:
- 3;
- and
- wherein said light chain variable domain comprises a CDR L1 as set forth in SEQ ID NO:
- 4, a CDR L2 as set forth in SEQ ID NO:5 and a CDR L3 as set forth in SEQ ID NO:6.
An anti-RYK antibody comprising a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain comprises a CDR H1 as set forth in SEQ ID NO:17, a CDR H2 as set forth in SEQ ID NO:
- 18, and a CDR H3 as set forth in SEQ ID NO:
- 19;
- and
- wherein said light chain variable domain comprises a CDR L1 as set forth in SEQ ID NO:
- 20, a CDR L2 as set forth in SEQ ID NO:21 and a CDR L3 as set forth in SEQ ID NO:22.
An anti-RYK antibody comprising a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain comprises a CDR H1 as set forth in SEQ ID NO:33, a CDR H2 as set forth in SEQ ID NO:34, and a CDR H3 as set forth in SEQ ID NO:35;
- and
- wherein said light chain variable domain comprises a CDR L1 as set forth in SEQ ID NO:
- 36, a CDR L2 as set forth in SEQ ID NO:37 and a CDR L3 as set forth in SEQ ID NO:38.
An anti-RYK antibody comprising a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain comprises a CDR H1 as set forth in SEQ ID NO:49, a CDR H2 as set forth in SEQ ID NO:50, and a CDR H3 as set forth in SEQ ID NO:51;
- and
- wherein said light chain variable domain comprises a CDR L1 as set forth in SEQ ID NO:
- 52, a CDR L2 as set forth in SEQ ID NO:53 and a CDR L3 as set forth in SEQ ID NO:54.
An anti-RYK antibody, wherein said anti-RYK antibody binds the same epitope as an antibody comprising:
- a heavy chain variable domain comprising a CDR H1 as set forth in SEQ ID NO:
- 1, a CDR H2 as set forth in SEQ ID NO:2, and a CDR H3 as set forth in SEQ ID NO:
- 3, and a light chain variable domain comprising a CDR L1 as set forth in SEQ ID NO:4, a CDR L2 as set forth in SEQ ID NO:5 and a CDR L3 as set forth in SEQ ID NO:6.
An anti-RYK antibody, wherein said anti-RYK antibody binds the same epitope as an antibody comprising:
- a heavy chain variable domain comprising a CDR H1 as set forth in SEQ ID NO:
- 17, a CDR H2 as set forth in SEQ ID NO:
- 18, and a CDR H3 as set forth in SEQ ID NO:
- 19, and a light chain variable domain comprising a CDR L1 as set forth in SEQ ID NO:
- 20, a CDR L2 as set forth in SEQ ID NO:21 and a CDR L3 as set forth in SEQ ID NO:22.
An anti-RYK antibody, wherein said anti-RYK antibody binds the same epitope as an antibody comprising:
- a heavy chain variable domain comprising a CDR H1 as set forth in SEQ ID NO:33, a CDR H2 as set forth in SEQ ID NO:34, and a CDR H3 as set forth in SEQ ID NO:35, and a light chain variable domain comprising a CDR L1 as set forth in SEQ ID NO:
- 36, a CDR L2 as set forth in SEQ ID NO:37 and a CDR L3 as set forth in SEQ ID NO:38.
An anti-RYK antibody, wherein said anti-RYK antibody binds the same epitope as an antibody comprising:
- a heavy chain variable domain comprising a CDR H1 as set forth in SEQ ID NO:49, a CDR H2 as set forth in SEQ ID NO:50, and a CDR H3 as set forth in SEQ ID NO:51, and a light chain variable domain comprising a CDR L1 as set forth in SEQ ID NO:
- 52, a CDR L2 as set forth in SEQ ID NO:53 and a CDR L3 as set forth in SEQ ID NO:54.
A method of forming an antibody capable of binding to a RYK protein, said method comprising immunizing a mammal with a peptide comprising the sequence of SEQ ID NO:
- 129.
A method of identifying an anti-RYK antibody, the method comprising:
- (i) contacting an antibody with a first RYK polypeptide comprising an amino acid sequence corresponding to amino acid residues 48 through 57 of SEQ ID NO:
- 129;
- (ii) detecting said antibody binding to said first RYK polypeptide;
- (iii) contacting said antibody with a second RYK polypeptide not comprising an amino acid sequence corresponding to amino acid residues 48 through 57 of SEQ ID NO:129;
- and
- (iv) detecting said antibody not binding to said second RYK polypeptide, thereby identifying an anti-RYK antibody.
Dependencies are inferred from the claim text.